Skip to main content

Table 4 Association between biomarker serum levels and outcome

From: Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Serum biomarker PFS OS
Median (days) HR (95 % CI) Median (days) HR (95 % CI)
P value P value
VEGF-A low-level baseline 166 0.533 329 0.602
high-level baseline 91 (0.318–0.895) 270 (0.356–1.018)
P  = 0.017 P = 0.058
sVEGFR2 low-level baseline 107 1.682 293 1.148
high-level baseline 167 (1.014–2.789) 330 (0.648–1.927)
P  = 0.044 P = 0.601
VEGF-D low-level baseline 123 1.670 310 0.888
high-level baseline 159 (0.760 –3.673) 300 (0.527–1.496)
P = 0.200 P = 0.654
SDF-1α low-level baseline 160 0.749 300 0.783
high-level baseline 129 (0.417–1.321) 329 (0.429–1.431)
P = 0.310 P = 0.427
  1. HR hazard ratio, PFS progression free survival, OS overall survival, CI confidence interval. P < 0.05 marked in boldface